Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention

Treatment with the selective estrogen receptor modulator (SERM) tamoxifen for 5 years has produced dramatic breast cancer–related benefits in (a) the adjuvant setting, with 30% to 50% reductions in recurrence, contralateral disease, and mortality and (b) the prevention setting of healthy high-risk women, where tamoxifen reduces the risk of invasive and noninvasive breast cancer by 50%. Despite these striking data, adherence to tamoxifen is low, and low adherence is associated with poor survival. Although toxicity is a major predictor of poor adherence after starting therapy, pretreatment (baseline) predictors of poor tamoxifen adherence have been minimally studied. The adherence–survival link underscores the critical need to identify early predictors of poor adherence, and recent work is beginning to address this need. A major baseline predictor of poor adherence to prevention is current smoking, which is interestingly absent from studies of adherence to adjuvant therapy. Other important prevention adherence factors include breast cancer risk, extremes of age, non-white ethnicity, low socioeconomic status, and alcohol use. The strongest adjuvant therapy predictors are age (especially very young), ethnicity, and socioeconomic status. Future studies involving prospective systematic evaluation of these and other potential predictors in endocrine chemoprevention (e.g., other SERMs and aromatase inhibitors) are critical, as is the development of effective/targeted interventions to improve adherence and thus treatment outcomes in at-risk women. Cancer Prev Res; 4(9); 1360–5. ©2011 AACR.

[1]  K. Calzone,et al.  Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[3]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[4]  J. Costantino,et al.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Brown,et al.  Tamoxifen prevention of breast cancer: an instance of the fingerpost. , 1999, Journal of the National Cancer Institute.

[6]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[8]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[10]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Regan,et al.  Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Grunfeld,et al.  Adherence beliefs among breast cancer patients taking tamoxifen. , 2005, Patient education and counseling.

[13]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[14]  D Gareth Evans,et al.  Predicting Compliance in a Breast Cancer Prevention Trial , 2006, The breast journal.

[15]  J. Costantino,et al.  Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[16]  Louise Atkins,et al.  Intentional and non-intentional non-adherence to medication amongst breast cancer patients. , 2005, European journal of cancer.

[17]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[18]  Ann H. Partridge Non-adherence to endocrine therapy for breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[20]  R. Chlebowski,et al.  Adherence to Endocrine Therapy for Breast Cancer , 2007, Oncology.

[21]  Eric C. Schneider,et al.  Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use , 2007, Medical care.

[22]  M. Zhan,et al.  Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. , 2007, Cancer detection and prevention.

[23]  L. Fallowfield,et al.  Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy , 2007, Breast Cancer Research and Treatment.

[24]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[25]  J. Costantino,et al.  Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) , 2008 .

[26]  C. Hudis,et al.  Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. , 2008, Clinical breast cancer.

[27]  A. Neugut,et al.  Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention , 2008, Health education & behavior : the official publication of the Society for Public Health Education.

[28]  Timothy L Lash,et al.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A M Thompson,et al.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer , 2008, British Journal of Cancer.

[30]  J. Rowland 4–48 Early Discontinuation of Tamoxifen: A Lesson for Oncologists , 2008 .

[31]  F. Camacho,et al.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Rimer,et al.  Longitudinal Predictors of Nonadherence to Maintenance of Mammography , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[34]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Hein Putter,et al.  Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Erika A. Waters,et al.  Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  C. Tarpin,et al.  Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view , 2010, Psycho-oncology.

[38]  M. Caleffi,et al.  Adherence to a Breast Cancer Screening Program and Its Predictors in Underserved Women in Southern Brazil , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[39]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[40]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[41]  J. Manson,et al.  Physical Activity and Survival in Postmenopausal Women with Breast Cancer: Results from the Women's Health Initiative , 2011, Cancer Prevention Research.

[42]  M. Rosenzweig,et al.  The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. , 2011, Oncology nursing forum.

[43]  W. Klein,et al.  Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial , 2011, Cancer Prevention Research.

[44]  Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.